Clinical trialPhase 1Terminated

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors

NCT01822756 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Stopped earlyDose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014. (Other)
Phase: Phase 1
Status: Terminated
Study type: Interventional
Start: April 2013
Expected end: August 2016
Enrollment: 42 participants
Sites: 5
Primary outcomes: Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)
Sponsor: Industry
Results posted: 2017-04-13
Last update: 12 February 2018

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a study of ruxolitinib in combination with gemcitabine with or without nab-paclitaxel administered to patients with advanced or metastatic pancreatic cancer. The study will be conducted in two parts. Part 1 of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of ruxolitinib when given as described to patients with advanced or metastatic pancreatic cancer. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of ruxolitinib when given with gemcitabine with or without nab-paclitaxel. This dose will be selected for use in Part 2 of the study. Part 2 of the study will further evaluate the safety, tolerability, PK and preliminary clinical activity of ruxolitinib at the dose defined in Part 1 used in combination with gemcitabine with or without nab-paclitaxel in subjects with advanced or metastatic pancreatic cancer. After multiple challenges of trial conduct, by mutual agreement between investigators and sponsor, dose escalation ended after Cohort B1, RUX 10 mg twice daily (BID) - GCSF in October 2014. Therefore, the MTD was not reached. No safety issues led to the decision to stop further enrollment. Because of the early study termination, samples for pharmacokinetics and pharmacodynamics, and computed tomography for tumor burden were collected, but not analyzed; analysis data are not available. The data cutoff for this posting is 22 SEP 2015. As of the data cutoff, 1 subject was receiving treatment in the study and had been enrolled for 47 weeks. This subject had their end of treatment visit in AUG 2016. A comparison of this subjects' safety data after the cutoff date showed no clinically meaningful differences (eg, adverse events) compared with safety results that are summarized here.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs) [Approximately 28 days]. Number, percentage of participants. Cohort A0 (n=16): 0.0; Cohort B (-1) (n=4): 0.0; Cohort B0 (+GCSF) (n=10): 20.0; Cohort B0 (-GCSF) (n=4): 50.0; Cohort B1 (n=8): 0.0.